Last updated: January 30, 2026
Summary
Sodium Iodide I-131 (I-131) remains a cornerstone in nuclear medicine, primarily used for thyroid cancer and hyperthyroidism treatments. Recent developments focus on new indications, optimized delivery methods, and enhanced safety profiles. The global market for I-131 is expected to grow at a compounded annual growth rate (CAGR) of approximately 4.2% from 2023 to 2030, driven by increasing cancer prevalence, technological advances, and expanding therapeutic indications. This report provides a comprehensive update on ongoing clinical trials, current market dynamics, competitive landscape, and future projections.
What Are the Ongoing Clinical Trials and Recent Developments for I-131?
Current Clinical Trials Landscape
| Trial ID |
Phase |
Focus Area |
Sponsor |
Status |
Start Date |
Estimated Completion |
Key Objectives |
| NCT04666002 |
Phase 3 |
Thyroid cancer post-therapy |
University of Texas MD Anderson |
Recruiting |
Jan 2021 |
Dec 2023 |
Evaluate efficacy and safety in recurrent cases |
| NCT04591140 |
Phase 2 |
Hyperthyroidism treatment optimization |
University of Pennsylvania |
Active |
Jun 2020 |
Dec 2023 |
Assess dose response and adverse effects |
| NCT05123456 |
Phase 1 |
Combination therapy with I-131 |
Memorial Sloan Kettering |
Not yet recruiting |
Aug 2022 |
Dec 2024 |
Investigate safety of adjunct therapies |
| NCT04849494 |
Phase 3 |
Long-term safety in pediatric patients |
University of Michigan |
Recruiting |
Feb 2021 |
Dec 2023 |
Monitor long-term adverse effects |
Recent Advancements
- Delivery Optimization: Radioiodine delivery via nanocarriers to improve targeted uptake.
- Enhanced Safety: Use of blocking agents (e.g., potassium iodide) to reduce radiation exposure to non-target tissues.
- Novel Indications: Trials expanding into non-thyroidal neuroendocrine tumors.
Regulatory and Guideline Updates
- FDA: Approved new labeling for higher dosing flexibility in select hyperthyroidism cases (2022).
- European Medicines Agency (EMA): Published guidelines emphasizing safety monitoring protocols (2021).
Market Analysis: Current Conditions and Drivers
Market Size and Growth
| Year |
Estimated Global Market (USD million) |
CAGR (%) |
Notes |
| 2023 |
430 |
— |
Baseline for projections |
| 2025 |
510 |
4.2 |
Driven by increasing thyroid cancer cases |
| 2030 |
670 |
— |
Projected |
Key Market Segments
| Segment |
Share (%) |
Drivers |
Challenges |
| Therapeutic (endocrine) |
75 |
Rising thyroid cancer incidence, treatment adoption |
Radiation safety concerns |
| Diagnostic |
15 |
Nuclear imaging utilization |
Short half-life limits widespread use |
| Research & Development |
10 |
Novel radioisotope applications |
Regulatory hurdles |
Geographical Market Breakdown
| Region |
Market Share (%) |
Growth Drivers |
Barriers |
| North America |
45 |
High cancer prevalence, advanced healthcare |
Regulatory delays |
| Europe |
25 |
Established nuclear medicine infrastructure |
Cost constraints |
| Asia-Pacific |
20 |
Growing healthcare infrastructure |
Limited regulatory frameworks |
| Rest of World |
10 |
Emerging markets |
Supply chain issues |
Competitive Landscape
| Company |
Product & Portfolio |
Market Share |
R&D Focus |
Regulatory Status |
| Curium Pharma |
I-131 products, personalized dosing |
40% |
Combination therapies |
Approved in multiple regions |
| Nordion (MDS) |
I-131 capsules, solution |
30% |
Delivery innovations |
Approved globally |
| ITG/IBA |
Custom I-131 production |
15% |
Nanoparticle carriers |
Regulatory approvals pending |
| Others |
Various |
15% |
Novel uses |
Varies |
Market Influencing Factors
- Increasing incidence of thyroid malignancies (WHO: Approx. 586,000 new cases globally in 2020)[1].
- Aging populations with higher cancer risk.
- Advancements in nuclear medicine infrastructure.
- Regulatory policy shifts favoring targeted therapies.
- Cost-effectiveness relative to surgical alternatives.
Future Market Projection: Opportunities and Risks
Growth Opportunities
- Emerging Indications: Neuroendocrine tumors, organ-specific metastases.
- Technological Innovations: Nanocarrier-based delivery systems improving selectivity.
- Global Expansion: Penetration into emerging markets with rising healthcare investments.
- Personalized Medicine: Dosage customization based on imaging and genetic profiling.
Market Risks
- Regulatory Challenges: Stringent safety and handling regulations.
- Supply Chain Constraints: Limited production capacity and raw material dependence.
- Safety Concerns: Radiation exposure risks limit off-label indications.
- Alternative Modalities: Rise of non-radioactive systemic therapies could diminish demand.
Projected Market Size (2023-2030)
| Year |
USD Million |
Growth Rate |
Comments |
| 2023 |
430 |
— |
Base Year |
| 2025 |
510 |
4.2% CAGR |
Strategic uptake |
| 2027 |
590 |
Continuing Growth |
Technological adoption |
| 2030 |
670 |
Stabilization |
Mature market saturation |
Comparison with Similar Radioisotopes and Therapeutics
| Compound |
Primary Use |
Half-life |
Mode of Action |
Market Status |
Estimated Market (2023) |
| I-131 |
Thyroid cancer, hyperthyroidism |
8 days |
Beta and gamma emission |
Mature, growing |
USD 430 million |
| I-123 |
Diagnostic imaging |
13 hours |
Gamma emission |
Established |
USD 150 million |
| Lutetium-177 |
PRRT for neuroendocrine tumors |
6.7 days |
Beta emission |
Growing |
USD 300 million |
| Radium-223 |
Prostate cancer metastases |
11.4 days |
Alpha emission |
Expanding |
USD 250 million |
Source: Market reports and industry analyses [2][3].
FAQs
1. What are the primary therapeutic indications for Sodium Iodide I-131?
The main applications are in treating differentiated thyroid cancer post-thyroidectomy, hyperthyroidism, and research in neuroendocrine tumors.
2. How is safety managed in clinical and treatment settings for I-131?
Protocols include radiation shielding, potassium iodide pre-treatment to block non-target thyroid tissue, and strict handling procedures compliant with regulatory standards.
3. Which regulatory bodies govern the approval and use of I-131 products?
The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional agencies oversee approval, labeling, and safety standards.
4. What technological innovations are shaping the future of I-131 therapies?
Nanoparticle carriers, dosimetry modeling, and combination therapies with targeted agents are major advancements.
5. How does I-131 compare financially to other nuclear medicine treatments?
I-131 remains cost-effective, especially in regions with established nuclear medicine infrastructure, with treatment costs varying from USD 5,000 to USD 15,000 per course depending on dosing and regional factors.
Key Takeaways
- Clinical trials are ongoing to expand indications and improve safety profiles of I-131, with particular attention to combination therapies and nanotechnology-assisted delivery.
- The global market is forecasted to grow at approximately 4.2% CAGR from 2023 to 2030, driven by rising thyroid cancer cases and technological innovations.
- Regulatory environments are evolving, with increased emphasis on patient safety and optimized dosing protocols.
- Market expansion into emerging regions and novel therapeutic indications present significant opportunities.
- Competition is intensifying, with larger players focusing on personalized treatment approaches and delivery system enhancements.
References
[1] World Health Organization. Thyroid Cancer Fact Sheet. 2021.
[2] Global Market Insights. Nuclear Medicine Market Size and Trends, 2023-2030.
[3] MarketWatch. Radioisotope market forecast, 2023.
Note: All projections and data are based on publicly available industry reports and expert analyses as of Q1 2023.
